LAUSR

Simple Summary Canine hemangiosarcoma is an aggressive cancer with a short median survival time, commonly found in the spleen of older dogs. There are limited tests available to provide clinically useful prognostic information to guide therapies once a diagnosis is made. Predictors of survivability investigated in this case series included the application of a previously published tumor histological grading scheme, histological assessment of tumor cell atypia, clinical staging, and the level of CD 31 expression by tumor cells in 16 dogs diagnosed with splenic hemangiosarcoma. Medical records were reviewed, the time of death was obtained, and survival data were analyzed statistically. Histopathological grading, cellular atypia, and clinical staging of canine splenic hemangiosarcomas were not significantly associated with the median survival time of the study dogs. Strong expression of CD 31 by canine splenic hemangiosarcoma tumor cells was observed in dogs with short survival times. This study provides a basis for future work to further investigate the prognostic usefulness of CD 31 expression for determining the survivability of canine splenic hemangiosarcoma patients. Abstract Canine hemangiosarcoma is a common, highly fatal tumor of older dogs, and predictors of survivability may provide clinically useful information. The objectives of this case series were to determine if a previously published tumor histological grading scheme, the level of tumor cellular atypia, clinical staging, or the level of CD 31 expression were useful for predicting the survival time in dogs with splenic hemangiosarcoma. Canine splenic hemangiosarcomas from 16 dogs were histologically graded, clinically staged, and assessed for CD 31 expression. Medical records were reviewed, the date of death was obtained, and survival data were analyzed statistically. Histopathological grading and clinical staging of canine splenic hemangiosarcomas, and the expression of CD 31 by the tumor cells were not significantly associated with the median survival time of the dogs in this study. However, strong expression of CD 31 by canine splenic hemangiosarcoma tumor cells was observed in dogs with short survival times, which warrants further studies to evaluate the potential prognostic value of CD 31 expression for the survival of dogs with splenic hemangiosarcoma.